Press Releases April 7, 2026 08:00 PM

Brookfield Asset Management to Host First Quarter 2026 Results Conference Call

Brookfield Asset Management schedules Q1 2026 earnings call and webcast for May 8, 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
BAM

Brookfield Asset Management Ltd. announced it will host a conference call and webcast on May 8, 2026, to discuss its first quarter 2026 results. The company will release earnings prior to the call, continuing its focus on managing a diverse portfolio of alternative assets including infrastructure, energy, private equity, real estate, and credit.

Brookfield Asset Management to Host First Quarter 2026 Results Conference Call
BAM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Brookfield Asset Management is a leading global alternative asset manager with over $1 trillion in assets under management.
  • The company operates across multiple sectors: infrastructure, energy, private equity, real estate, and credit, impacting the broader financial and economic markets.
  • The earnings call and webcast are scheduled for May 8, 2026, providing transparency to investors and stakeholders.

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. today announced it will host its first quarter 2026 conference call and webcast on Friday, May 8, 2026, at 10:00 a.m. ET.

Results will be released that morning prior to 7:00 a.m. ET and will be available on our website at www.bam.brookfield.com/news-events/press-releases.

Participants can join by conference call or webcast:

Conference Call

  • Please pre-register by conference call:
    https://register-conf.media-server.com/register/BI4a9ba8996eec4112a6842d2dbf312077
  • Upon registering, you will be emailed a dial-in number, and unique PIN. This process will bypass the operator and avoid the queue.

Webcast

  • Please join and register by webcast: https://edge.media-server.com/mmc/p/wptdyzxu

About Brookfield Asset Management

Brookfield Asset Management Ltd. (NYSE: BAM, TSX, BAM) is a leading global alternative asset manager, headquartered in New York, with over $1 trillion of assets under management across infrastructure, energy, private equity, real estate, and credit. We invest client capital for the long-term with a focus on real assets and essential service businesses that form the backbone of the global economy. We offer a range of alternative investment products to investors around the world — including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies and private wealth investors. We draw on Brookfield’s heritage as an owner and operator to invest for value and generate strong returns for our clients, across economic cycles.

For more information, please visit our website at www.bam.brookfield.com.

Media:
Simon Maine
Tel: (332) 298-0447 
Email: [email protected]Investor Relations:
Jason Fooks
Tel: (212) 417-2442
Email: [email protected]

Risks

  • The company’s performance is subject to economic and market cycles which can affect asset valuation and returns, particularly in real assets and infrastructure sectors.
  • Potential volatility in alternative asset sectors such as energy and private equity may impact financial results.
  • Global economic uncertainties and market conditions could influence investor sentiment and capital deployment strategies.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026